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Abstract
Background: Adjuvants serve as catalysts of the innate immune response by initiating a localized site of inflammation that
is mitigated by the interactions between antigens and toll like receptor (TLR) proteins. Currently, the majority of vaccines are
formulated with aluminum based adjuvants, which are associated with various side effects. In an effort to develop a new
class of adjuvants, agonists of TLR proteins, such as bacterial products, would be natural candidates. Lipopolysaccharide
(LPS), a major structural component of gram negative bacteria cell walls, induces the systemic inflammation observed in
septic shock by interacting with TLR-4. The use of synthetic peptides of LPS or TLR-4 agonists, which mimic the interaction
between TLR-4 and LPS, can potentially regulate cellular signal transduction pathways such that a localized inflammatory
response is achieved similar to that generated by adjuvants.
Methodology/Principal Findings: We report the identification and activity of several peptides isolated using phage display
combinatorial peptide technology, which functionally mimicked LPS. The activity of the LPS-TLR-4 interaction was assessed
by NF-kB nuclear translocation analyses in HEK-BLUE
TM-4 cells, a cell culture model that expresses only TLR-4, and the
murine macrophage cell line, RAW264.7. Furthermore, the LPS peptide mimics were capable of inducing inflammatory
cytokine secretion from RAW264.7 cells. Lastly, ELISA analysis of serum from vaccinated BALB/c mice revealed that the LPS
peptide mimics act as a functional adjuvant.
Conclusions/Significance: Our data demonstrate the identification of synthetic peptides that mimic LPS by interacting with
TLR-4. This LPS mimotope-TLR-4 interaction will allow for the development and use of these peptides as a new class of
adjuvants, namely TLR-4 agonists.
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Introduction
Lipopolysaccharide (LPS) is the major structural component of
gram negative bacteria and is composed of three distinct domains;
lipid A, a core oligosaccharide chain, and an O-antigen [1,2]. Of all
threeLPSdomainsdiscussed,theO-antigenisofmostsignificanceas
it distinguishes between various gram negative bacterial strains and
most importantly, it is recognized by the immune system during
infection [2,3]. It is this recognition and interaction between LPS
and the immune system, specifically the innate branch of the
immune system, which leads to a potentially life threatening
condition known as sepsis. Septic shock remains the number one
cause of death in intensive care units and is responsible for 750,000
new cases with 250,000 of these new cases resulting in death within
the US [4,5,6]. Death by septic shock is attributed to the
inflammatory cytokines released by members of the innate immune
system,suchasantigenpresentingcells(APC),whichultimatelyleads
to dysfunction and failure of the body’s major organ systems [7,8,9].
Inflammatory cytokine secretion occurs upon the initial
interaction between LPS and its receptor, toll like receptor 4
(TLR-4), present on APCs such as macrophages and dendritic cells
[10,11]. TLR-4 belongs to a family of transmembrane receptors,
originally identified in Drosophila [12], which are responsible for
recognizing and responding to pathogen associated molecular
patterns (PAMPS) such as LPS [2]. Upon activation of TLR-4, a
series of signal transduction events occur ultimately leading to
nuclear translocation of transcription factor NF-kB, subsequently
resulting in transcription of various inflammatory cytokines such as
TNF-a, IL-1b, and IL-12p70 [13,14]. Collectively, these inflam-
matory cytokines are responsible for the systemic inflammatory
response syndrome [7,9] observed during septic shock. Although
responsible for causing systemic inflammation, the inflammatory
response associated with LPS may be beneficial if the signal
transduction initiated by LPS, which is similar to that observed in
adjuvants, can be optimally regulated.
Adjuvants are substances that accelerate and/or enhance an
antigen specific immune response as antigens alone are not
recognized by the immune system [15]. Thus the sole purpose of
an adjuvant is to make an antigen visible to the eyes
(macrophages/dendritic cells) of the immune system. Recognition
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events leading to localized inflammation, which recruits APCs and
ultimately leads to initiation of a productive cell and/or antibody
mediated immune response [15]. Although various adjuvants exist,
not all are approved for human use and the adjuvants which are
approved are associated with adverse side effects such as malaise
and inflammation [15]. Currently, the majority of human vaccines
contain aluminum salts as an adjuvant while pharmaceutical
companies are developing oil-based adjuvants to be incorporated
into vaccines [15]. Another class of adjuvants which is gaining
interest is TLR agonists merely because TLRs are the prime
initiators of inflammation [16]. Currently, adjuvants which act as
agonists to TLR-2, TLR-5, TLR7/8, and TLR-9 are being
studied [17–20] and one TLR-4 agonist, monophosphoryl lipid A,
is FDA approved [21,22]. Although promising, many of these
agonists are bacterial molecules, which brings to light the possible
development and/or use of synthetic peptides as TLR agonists and
hence adjuvants.
As mentioned, the potent inflammation induced by LPS
activation of APCs via TLR-4 suggests LPS to be an optimal
adjuvant only if the inflammation remains localized. One way to
exploit the inflammatory properties of LPS such that it can be used
as an adjuvant but lack its detrimental side effects is through
identification of synthetic LPS peptide mimics using Phage display
peptide libraries. To date, no studies have used LPS as a target to
identify peptides from Phage display libraries but one study
identified peptide mimics of H. influenzae lipooligosaccharide (LOS)
to be possibly developed into a H. influenzae vaccine [23]. The
study in the present manuscript was designed to identify LPS
peptide mimics, using Phage display libraries that can be
developed into a new class of synthetic peptide TLR-4 agonist
adjuvants, thus eliminating the use of bacterial proteins/lipids.
Various peptides were identified that functionally mimicked LPS
by inducing nuclear translocation of NF-kB, which was measured
by a colorimetric assay involving the use of a TLR-4 expressing
transgenic cell line, HEK-BLUE
TM-4, as well as Western blot and
fluorescence microscopy. In addition, because the inflammation
induced by LPS is a consequence of inflammatory cytokine release
from activated APCs, we utilized the macrophage cell line
RAW264.7, which expresses TLR-4, and observed that various
inflammatory cytokines are released upon activation by the LPS
mimics. Lastly and most significant, the LPS peptide mimics were
capable of functioning as adjuvants in in vivo immunization
experiments as determined by the increased levels of antibodies in
mice that received a vaccine containing the LPS peptide mimic
and a prostate cancer specific antigen. Therefore, the peptides
identified in this study functionally mimic LPS and have the
potential to be developed into a novel TLR-4 agonist adjuvant.
Results
LPS peptide mimics stimulate TLR-4 and activate HEK-
BLUE
TM cells
Phage display technology is a powerful tool used to identify
peptides which can be used in many down stream applications
such as identification of specific inhibitors or activators of certain
target proteins [24,25]. In this study, Phage display was used for
identification of twelve 7-mer peptides (Table 1), which were
mimics of LPS as determined by ELISA (Fig. 1). Each clone
reacted with the immobilized LPS antibody (black bars) but not
with a non-specific antibody such as Hsp70 (white bars), which was
used as a negative control (Fig. 1). All twelve peptides were then
assayed for their ability to bind to TLR-4 and subsequently
activate NF-kB using a transgenic HEK293 cell line known as
HEK-BLUE
TM-4. This cell line is stably transfected to only
express TLR-4 on its plasma membrane, with no other TLRs
present. Activation of NF-kB is made possible because secreted
alkaline phosphatase (SEAP) is under the control of the NF-kB
promoter. Therefore, NF-kB activation leads to SEAP secretion,
which is detected by an alkaline phosphatase substrate in cell
culture media. For all peptides, three concentrations (1 mg/ml
(black bars), 5 mg/ml (gray bars), and 10 mg/ml (white bars) were
used to activate HEK-BLUE
TM-4 cells. LPS (0.1 mg/ml) was used
as a positive control. Normal media was used as a negative control
to assure that it did not contain any substances, such as
endogenous alkaline phosphatases, which could be detected by
the assay. DMSO was used as a control for peptide RS04 which
was not water soluble (Fig. 2A). Of the seven peptides shown in
figure 2A, Peptides RS011, RS03, and RS04 were considered as
TLR-4 stimulating and hence activators of NF-kB. The activity of
peptides RS08-RS12 is shown in figure 2B in which peptides
RS09, RS11, and RS12 were considered as positive for TLR-4
stimulation and NF-kB activation.
LPS peptide mimics induce nuclear localization of NF-kB
The main event which occurs upon binding of LPS to TLR-4 is
nuclear localization of the transcription factor NF-kB, which upon
binding to its promoter, results in transcription of inflammatory
cytokines; an event at the heart of septic shock [13,14]. Therefore
we wanted to observe if two peptides selected at random, peptide 1
(RS01) and peptide 9 (RS09), were capable of binding to TLR-4
and inducing nuclear localization of NF-kB in the macrophage cell
line RAW264.7. We also assayed for nuclear localization in HEK-
BLUE
TM-4 cells side by side with RAW264.7 as a comparison.
Both RAW264.7 and HEK-BLUE
TM-4 cells were incubated with
either RS01 or RS09 followed by processing the cells for both
cytoplasmic and nuclear protein fractions. LPS was used as a
positive control for both cell lines. In RAW264.7, nuclear NF-kB
was absent in non-stimulated cells and increased during the
indicated times of 15, 30, 60, and 120 min (Fig. 3A). In an
inactivated state, NF-kB is sequestered within the cytoplasm by
IkB-a, which becomes ubiquinated and degraded upon cellular
activation thus releasing NF-kB for nuclear transit. Western blot
analysis demonstrated that as nuclear translocation of NF-kB
increases over time, so too does the degradation of IkB-a, within
the cytoplasm. As expected, concentrations of cytoplasmic NF-kB
Table 1. LPS Specific Phage Peptide Sequences.
Phage Clone Peptide Sequence
RS01 Gln Glu Ile Asn Ser Ser Tyr
RS02 Ser His Pro Arg Leu Ser Ala
RS03 Ser Met Pro Asn Pro Met Val
RS04 Gly Leu Gln Gln Val Leu Leu
RS05 His Glu Leu Ser Val Leu Leu
RS06 Tyr Ala Pro Gln Arg Leu Pro
RS07 Thr Pro Arg Thr Leu Pro Thr
RS08 Ala Pro Val His Ser Ser Ile
RS09 Ala Pro Pro His Ala Leu Ser
RS10 Thr Phe Ser Asn Arg Phe Ile
RS11 Val Val Pro Thr Pro Pro Tyr
RS12 Glu Leu Ala Pro Asp Ser Pro
doi:10.1371/journal.pone.0030839.t001
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within the nucleus. Similar results pertaining to increased nuclear
localization of NF-kB with simultaneous decrease of cytoplasmic
IkB-a and NF-kB were observed with HEK-BLUE
TM-4 cells
(Fig. 3B). For nuclear protein extracts, histone deacetylase 1
(HDAC1) was used as a loading control and for cytoplasmic
protein extracts, actin was used as a loading control (Fig. 3A and
3B). Lastly, to demonstrate that RS01 and RS09 indeed bind to
TLR-4 leading to NF-kB activation, non-TLR-4 expressing
HEK293 cells were used as a negative control. No differences in
the levelsof NF-kB wereobserved withinthe cytoplasmand nucleus
suggesting that HEK293 cells treated with either LPS, RS01, or
RS09 did not result in nuclear translocation due to the lack of TLR-
4 (Fig. 3C). To further demonstrate activation and nuclear
translocation of NF-kB in RAW264.7, fluorescence microscopy
was performed with peptides RS01 and RS09, with LPS being used
as a positive control (Fig. 4). NF-kB in control cells was located
within the cytoplasm as observed by the diffuse green staining cells
which are better visualized upon the merge with the DAPI stained
blue nucleus. When comparing LPS, RS01, and RS09 stimulated
RAW264.7 cells, the green staining NF-kB appears more rounded
and not diffuse as in the control cells indicating nuclear localization,
which was confirmed upon the merge with the DAPI stained blue
nucleus resulting in teal colored nuclei (Fig. 4).
Activated RAW264.7 Macrophages Secrete Inflammatory
Cytokines
Inflammation results from binding of nuclear NF-kBt oi t s
promoter, thus initiating transcription of various cytokines.
Development of the LPS peptide mimics identified in this study
as an adjuvant would require them to induce secretion of pro-
inflammatory cytokines, which in turn activate the immune
system and initiate an antigen specific immune response.
Provided that a broad range of cytokines and chemokines are
secreted during an inflammatory response, we utilized antibody
array membranes to determine which cytokines/chemokines
were secreted in response to the LPS peptide mimics RS01 and
RS09. Although the values obtained for each cytokine are not
quantitative but rather qualitative, they did serve in giving one
an idea as to the various inflammatory cytokines secreted. These
values were calculated and presented as IDV, which is the
density of each spot compared to the density of the internal
positive controls present on each membrane. Values for the
various cytokines and chemokines detected are presented in
Figure 5A for RS01 and Figure 5B for RS09 in which the
squares represent cytokines secreted upon LPS stimulation and
the triangles represent cytokines secreted upon peptide RS01/
RS09 stimulation. Both peptides were capable of inducing
secretion of inflammatory cytokines and chemokines from
RAW264.7 cells, which was comparable to those secreted from
LPS stimulated cells.
LPS peptide mimics function as adjuvants in vivo
Weakly or non-immunogenic antigens require an adjuvant
that can activate the innate immune system and subsequently
initiate an antigen specific immune response. Having observed
that the RS01 and RS09 LPS peptide mimics identified in our
study were not only capable of inducing NF-kBn u c l e a r
Figure 1. Identification of LPS specific peptide mimotopes. LPS antibody was immobilized at a concentration of 1 mg per well of a 96-well
plate. Phages (2610
11) expressing 7-mer peptides were initially added to the well of a 96-well plate containing immobilized LPS antibody after which
non-specific phages were removed. Twelve random phage clones were selected from three rounds of panning and specificity to LPS antibody (black
bars) was confirmed by ELISA using HSP70 antibody (white bars) as a negative control. All 12 (RS01-RS12) clones selected displayed specific reactivity
to LPS antibody, as determined using the HRP labeled anti-M13 phage antibody which was detected by the HRP substrate SIGMAFAST
TM OPD and
absorbance measured at 490 nm. Each experiment was repeated three times with similar results observed and the standard deviation shown above
each sample represents three replicates in one experiment.
doi:10.1371/journal.pone.0030839.g001
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from RAW264.7 macrophages, we next determined if they
could function as an adjuvant in vivo. The antigen used for our in
vivo adjuvant study is a 15-mer peptide, known as X-15, which
has been observed to possess prostate tumor protective
properties in vivo when administered with an adjuvant [26].
Figure 2. LPS peptide mimics activate NF-kB is HEK-BLUE
TM-4. LPS peptide mimics were dissolved in endotoxin free water and added to 96-
well plates at three concentrations; 1 mg/ml (black bar), 5 mg/ml (gray bar), and 10 mg/ml (white bar). HEK-BLUE
TM-4 were then added to each well at
a concentration of 5610
4 cells per well in complete media. The supernatant was then harvested after 24 h and assayed for alkaline phosphatase
secretion indicating activation of NF-kB. NF-kB activation for peptides RS01-RS07 is represented in figure 2A and peptides RS08-RS12 in figure 2B. LPS
was used as a positive control in assaying all peptides for NF-kB activation. Absorbance was taken at 630 nm. Each experiment was repeated three
times with similar results observed and the standard deviation shown above each sample represents three replicates in one experiment.
doi:10.1371/journal.pone.0030839.g002
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alum and used as an immunogen to vaccinate BALB/c mice.
Serum X-15 specific antibody concentrations are shown in
Figure 6. Interestingly, despite our observation that both
peptides possessed properties typical of an adjuvant in vitro,
only RS09 was capable of producing a robust X-15 antibody
response when compared to Alum and RS01 in vivo.T h i s
significant increase in X-15 specific antibody concentration with
RS09 was observed on day 28 (white bar) post vaccination as
s h o w ni nF i g u r e6 .R S 0 1a n dR S 0 9w e r eg i v e na ta
concentration of 25 mg during the initial vaccination on day 0
and during the booster on day 14. Twenty five micrograms was
chosen as a starting concentration as this dose, in our experience
with using peptides as vaccines, does not induce an antibody
response and hence is non-immunogenic. To confirm this
observation, two groups of 3 mice were vaccinated with either
25 mg of RS01 or RS09 and no antibodies were produced in
these mice (data not shown). This was significant in that RS01
and RS09 were not immunogenic at the concentration used as
an adjuvant but were capable, in t h ec a s eo fR S 0 9 ,o fe n h a n c i n g
production of X-15 specific antibodies.
Discussion
Adjuvants provide a bridge between antigens and APCs of
the immune system [27]. In theory, an adjuvant can be
considered a catalyst because in its absence, weakly immuno-
genic or non-immunogenic antigens such as peptides would
essentially remain invisible to the immune system. This
adjuvant driven immune response is made possible by an
inflammatory response, which relies on activation of APCs thus
setting the stage for an antigen specific immune response [28].
The inflammatory response is initiated by a cell signal
transduction cascade initiated by the TLR proteins, specifically
TLR-4, resulting in NF-kB driven transcription of potent
inflammatory cytokines and chemokines [29].
Figure 3. LPS peptide mimics lead to NF-kB nuclear translocation. Nuclear translocation studies of NF-kB were performed by Western blot
analysis on both RAW264.7 (Fig. 3A), HEK-BLUE
TM-4 (Fig. 3B), and HEK293 (Fig. 3C) cells. Cells were stimulated with peptide, either RS01or RS09, at a
concentration of 5 mg/ml per 5610
4 cells at various time points (15, 30, 60, and 120 min). Nuclear protein fractions were assayed for NF-kB while
cytoplasmic proteins fractions were assayed for both NF-kB and IkB-a. HDAC was used as a nuclear protein loading control and actin was used as a
cytoplasmic protein loading control. For HEK293 cells, no differences in the levels of cytoplasmic and nuclear NF-kB were observed suggesting that
LPS, RS01, and RS09 do not activate the non-TLR-4 expressing HEK293 cells (Fig. 3C).
doi:10.1371/journal.pone.0030839.g003
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bark of the soap tree, and oil based emulsions are being evaluated
in clinical trials for their efficacy. Currently, alum based adjuvants
and monophosphoryl lipid A, a bacterial product, remain the only
FDA approved adjuvants [15,21,22]. Therefore, identification of
new adjuvants, such as synthetic TLR-4 agonists, can serve as
potential candidates and when considering compounds that can
act as agonists of TLR-4, the bacterial cell wall component, LPS, is
of prime significance. Classically, LPS is considered a very potent
inducer of systemic inflammation, which underlies the condition
known as sepsis or septic shock [29,30]. Despite the negative
affects attributed to LPS in septic shock, identification of
compounds which can induce inflammation like LPS, but not on
a systemic scale, will allow their use as adjuvants.
Identification of compounds which mimic LPS by initiating the
essential inflammatory events that are required during an
immune response and thus be developed into a potential adjuvant
was the goal of this study. Several LPS peptide mimotopes
identified in this study were capable of mimicking two essential
events that are observed during LPS induced inflammation;
namely activation of cells via TLR-4, resulting in nuclear
translocation of NF-kB and secretion of inflammatory cytokines.
Consistently, all the peptides chosen to assay for their NF-kB
activating ability, using the TLR-4 expressing transgenic HEK-
BLU
TM-4, displayed differential activity while other peptides
were non-activating. Due to the fact that the HEK-BLU
TM-4 cell
line expresses TLR-4 exclusively, it confirmed that these peptides
acted as mimics of LPS. LPS activation of TLR-4, resulting in
initiation of a signal transduction cascade culminating in NF-kB
activation/nuclear translocation, was also observed to be true for
the two peptides assayed for in our study (RS01 and RS09). Both
peptides RS01 and RS09 were observed to initiate nuclear
translocation of NF-kB in the murine macrophage cell line,
RAW264.7 as well as in HEK-BLU
TM-4. This observation using
RAW264.7 was more significant to this study as it is a
macrophage cell line and hence interaction with TLR-4 thus
ensuing NF-kB activation lend in vivo significance and credence
for adjuvant activity. Interestingly, for the nuclear translocation
experiments, both by Western blotting and fluorescence micros-
copy, LPS was used as a positive control and displayed similar
activity to that of RS01 and RS09 indicating our peptides to be
true LPS peptide mimics. It is important to mention that the
kinetics of nuclear NF-kB translocation was greater for LPS that
both RS01 and RS09 in HEK-BLU
TM-4 and RAW264.7 cells.
This infers that LPS generates a more rapid and robust immune
response compared to RS01 and RS09 but this is a favorable
observation with respect to developing RS01 and RS09 into
adjuvants. Ideally, we want the immuno-stimulatory response of
that observed with RS01 and RS09 and not that of LPS, which
can potentially lead to an exaggerated immune response as that
observed in septic shock syndrome.
One critical event addressed in our study was if our LPS peptide
mimics were capable of inducing secretion of cytokines that initiate
an inflammatory response. Provided that both RS01 and RS09
were active at the level of NF-kB nuclear translocation, both RS01
and RS09 were assayed for cytokine expression studies. Inflam-
matory cytokine secretion in RAW264.7 was similar for LPS,
RS01, and RS09. The cytokines detected ranged from pro-
inflammatory cytokines such as TNF-a, IL-1b, and IL-12p70 to
chemokines such as MCSF, GCSF and GM-CSF, which are
crucial chemo attractants and activators of macrophages and
leukocytes. All of the cytokines detected cooperate in activating the
innate immune system, in response to antigen, thus initiating
inflammation. Initiation of this inflammatory response is what
defines an adjuvant, such as the LPS peptide mimics identified in
this study.
Lastly, in order to validate our claim that these LPS peptide
mimics can act as adjuvants, in vivo experiments were performed in
BALB/c mice. Knowing fully well that results observed in in vitro
experiments do not always correlate or translate into in vivo
experiments, both peptides (RS01 and RS09) were individually
used as an adjuvant in the animal studies and the immunogen used
was a prostate cancer specific antigen, X-15. Interestingly, only
one peptide, RS09, was capable of increasing X-15 specific
antibodies in vivo. The fact that RS01 did not react as RS09 in vivo
needs further examination but can be contributed to various
Figure 4. Fluoresence microscopy of NF-kB nuclear translocation. RAW264.7 macrophages were seeded in 8 well chamber slides at a density
of 2610
4 cells per well and stimulated with 5 mg/ml of either RS01 or RS09. After 30 min incubation, cells were fixed (4% para-formaldehyde),
permeabilized (0.2% Triton X-100), blocked (10% goat serum/1% BSA), and incubated with anti-NF-kB followed by DAPI staining of nuclei. The stained
cells were visualized using the Axiovert 200 M microscope with a 406 magnification. NF-kB (green) was more diffusely spread throughout the
cytoplasm in control cells but appeared more circular in RS01, RS09, and LPS treated cells. Upon merging green NF-kB with DAPI nuclei, nuclear
localization of NF-kB was observed by the teal color in treated but not in control cells.
doi:10.1371/journal.pone.0030839.g004
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6
cells per well of a six well plate followed by addition of either RS01 (Fig. 5A) or RS09 (Fig. 5B) and incubated for 24 h after which the culture media
was collected. LPS was used as a positive control for both RS01 and RS09 and therefore represented on both Figures 5A and 5B. Culture media was
then analyzed for specific cytokine using an antibody array kit. Both RS01 (triangle) and LPS (square) were capable of inducing inflammatory
cytokines and chemokines from RAW264.7. Each cytokine is represented as an IDV value which was calculated by comparing the density of each spot
with respect to the density of the internal positive controls. The antibody array represents a qualitative comparison of each cytokine and is not
qualitative. Each experiment was repeated three times with similar results observed and the standard deviation shown above each sample represents
three replicates in one experiment.
doi:10.1371/journal.pone.0030839.g005
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used as an adjuvant may not be optimal to activate APCs in vivo,
thus requiring further experiments with varying RS01 concentra-
tions. Secondly, the RS01 peptide may need to be administered as
an emulsion such that it remains localized when administered with
an immunogen. In our experiments, both RS01 and RS09 were
not formulated as an emulsion with the X-15-KLH immunogen
but added in a PBS suspension. Nevertheless, our observation that
RS09 increased antibody production in a vaccine setting suggests
that this LPS peptide mimic can function as an adjuvant and thus
serve as a novel candidate to be considered as a new class of TLR-
4 agonist adjuvants.
Materials and Methods
Cell Culture
RAW264.7 and HEK293 cells were purchased from ATCC
(ATCC, Manassas, VA) and were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA), penicillin 10,000 IU/ml, streptomycin
10,000 mg/ml (Mediatech, Herndon, VA), Plasmocin
TM antibiotic
2.5 mg/ml (Invivogen, San Diego, CA), and 2 mM L-glutamine
(Mediatech). HEK-BLUE
TM-4 cells were purchased from Invivo-
gen and were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS) (Atlanta Biologicals), penicillin 10,000 IU/ml,
streptomycin 10,000 mg/ml (Mediatech), Normocin
TM 100 mg/ml
(Invivogen), 16 HEK-BLUE
TM selection antibiotics mixture
(2 ml/500 ml complete media) (Invivogen), and 2 mM L-gluta-
mine (Mediatech).
Phage Display
Identification of the LPS peptide mimics was performed by
using a 7-mer Phage display peptide library referred to as Ph.D.-7
(New England BioLabs, Ipswich, MA). Panning was performed
according to manufactures specifications using a LPS specific
antibody as the target. The LPS antibody (Abcam, Cambridge,
MA, CAT# ab35654) used for the panning was a monoclonal
antibody, which was produced by vaccinating mice with whole
Escherichia coli O111B4J5 cells. Although it is not known by the
manufacturer as to which structural component of LPS is
recognized by the antibody, it is specific to LPS and has been
used in various publications [31,32]. Briefly, 1 mg of the LPS
antibody was absorbed to one well of a 96 well plate in a total
volume of 100 ml of PBS overnight at 4uC. Phages (2610
11) were
added to the well and allowed to adhere at room temperature after
which non-binding phages were washed away and bound phages
eluted. Eluted phages were subsequently amplified and used for
further panning so as to enrich for LPS antibody specific phages.
The panning procedure described was repeated three times.
Lastly, twelve random phage clones were selected from three
rounds of panning and specificity to LPS antibody (black bars) was
confirmed by ELISA using HSP70 antibody (ENZO life sciences,
Farmingdale, NY) (white bars) as a negative control. The species
for both the anti-LPS and anti-HSP70 antibodies used were
mouse. Bound phages were detected by using a HRP labeled anti-
M13 phage antibody (Abcam) followed by adding the HRP
substrate SIGMAFAST
TM OPD (Sigma, St. Louis, MO) and
absorbance measured at 490 nm using a microplate reader (Bio-
Rad, Hercules, CA). The panning, titer determination, and ELISA
Figure 6. RS09 functions as an adjuvant in vivo. Four groups of mice (3 mice/group) were vaccinated with X-15 (100 mg) conjugated to KLH. The
mice were bled on days 0, 14, and 28. The serum obtained from each animal was analyzed for presence of X-15 specific antibodies by direct ELISA
with immobilized X-15 peptide. The difference between groups was the adjuvant used, which was Alum, RS01 or RS09. OVA peptide (8-mer peptide)
was used as a negative peptide control. As shown in figure 6, the highest X-15 specific antibody concentration was observed on Day 28 post
vaccination (White bars) for all groups. RS09 was the only peptide capable of enhancing the X-15 specific antibody response on day 28. The standard
deviation represents triplicate values for each group of animals.
doi:10.1371/journal.pone.0030839.g006
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protocol. Once their reactivity was determined, the DNA
encoding the peptide sequence from each positively reacting
phage clone was purified using QIAprep Spin M13 Kit (Qiagen,
Valencia, CA) and were sequenced by Genewiz (Genewiz, South
Plainfield, NJ) using the primers supplied in the kit (New England
BioLabs). The LPS peptide mimics sequenced were synthesized by
Genemed Synthesis and their purity was greater than 95%
(Genemed Synthesis, San Antonio, TX).
NF-kB Activation Assay
The LPS peptide mimics synthesized were dissolved in
endotoxin free water (HyClone) at a concentration of 1 mg/ul
with the exception of peptide 4 which was dissolved in a solution of
1% DMSO made in endotoxin free water at a 1 mg/ul
concentration. All of the peptide stock solutions and stored at
280uC until they were used. Each of the 12 peptides (RS01-RS12)
was added to 96-well plates in triplicates in a total volume of 20 ml.
The total volume required in each well was made up with
endotoxin free water (HyClone). HEK-BLUE
TM-4 cells (Invivo-
gen, San Diego, CA), 5610
4 cells, were added per well and
incubated for approximately 20 h after which the supernatant
from each well was collected and placed into a new 96-well plate.
One hundred eighty micro liters of HEK-BLUE
TM detection
media (Invivogen), alkaline phosphatase detection substrate, was
added to each well and incubated for 1–3 h at 37uC. After a
noticeable color change, the absorbance was taken at 630 nm
using the microplate reader (Bio-Rad).
NF-kB Nuclear Translocation Western Blot
Cytoplasmic and nuclear protein extracts were prepared from
HEK-BLUE
TM-4, HEK293, and RAW264.7 cells (2610
6 cells)
using NE-PER, nuclear and cytoplasmic extraction reagent kit
(PIERCE, Rockford, IL). Manufacturer’s protocol was followed to
separate cytoplasmic and nuclear fractions. Nuclear and cytoplas-
mic lysates (10 mg protein) were subjected to 12% SDS–PAGE
under reducing conditions (presence of b-mercaptoethanol) as
described earlier. Briefly, the proteins were transferred to
Immobilon-P membranes (Millipore, Billerica, MA) at 220 mA
for 2 h and membranes were blocked with 4% dried milk in TBST
[200 mM Tris–HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween-20
added fresh/liter of 16TBS (TBST)] for at least 2–3 h on a shaker
at room temperature. Subsequently, the membranes were
incubated overnight at 4uC with either NF-kB p65 (Cell Signaling
Technology, Danvers, MA), IkB-a (Cell Signaling Technology),
Actin (Santa Cruz Biotechnology, Santa Cruz, CA), or HDAC1
(Santa Cruz Biotechnology) antibodies in TBST on a shaker.
Membranes were then washed three times with TBST and then
incubated with the respective secondary antibody for 2 hrs at
room temperature on a shaker. After four washes with TBST and
one wash with TBS, membranes were developed by ECL (Pierce)
and detected on HyBlot CL
TM autoradiography film (Denville
Scientific, Inc, Metuchen, NJ).
NF-kB Nuclear Translocation Immuno Fluoresence
HEK-BLUE
TM-4 and RAW264.7 cells were seeded in 8-
chamber slides (BD Biosciences, Bedford, MA) at a density of
2610
4 cells per well. Cells were allowed to adhere at 37uC over
night after which the cells were stimulated with LPS peptide
mimics at various time points and subsequently processed for
immuno fluoresence. The cells were fixed with a 4% paraformal-
dehyde/PBS solution, followed by permeabilization with 0.2%
triton X-100, and lastly the cells were blocked using a solution of
0.1% triton X-100, 1% BSA, and 10% goat serum. The cells were
then incubated with the NF-kB p65 antibody (1:50) (Cell
Signaling) overnight at 4uC followed by incubation for 45 min at
room temperature with Alexa FluorH 488 labeled goat anti-rabbit
(1:250) (Invitrogen, Carlsbad, CA). The slides were then mounted
with VectashieldH containing DAPI (Vector Laboratories, Burlin-
game, CA). Cells were visualized using the Axiovert 200 M
microscope (Zeiss, Thornwood, NY)
Inflammatory Cytokine Detection
RAW264.7 cells were seeded at a density of 1610
6 cells per well
of a six well plate and allowed to adhere overnight at 37uC. Cells
were then stimulated with LPS peptide mimics for 24 h at 37uC
after which the cell culture supernatant was collected and assayed
for various secreted inflammatory cytokines by using the mouse
inflammation antibody array-1 kit (RayBioH, Norcross, GA).
Briefly, the membranes provided were blocked with 16 assay
diluent followed by incubation with the cell culture supernatant
overnight at 4uC. The blots were the incubated with biotin labeled
anti-cytokines followed by incubation with avidn-HRP (1:250).
The blots were then developed using ECL (Pierce) and detected on
HyBlot CL
TM autoradiography film (Denville Scientific). Detailed
instructions for detection of inflammatory cytokines were provided
by the manufacturer.
Animal studies to examine adjuvanticity
Eight week old male BALB/c mice (Charles River Laboratories,
Wilmington, MA) were divided into 4 groups (3 mice per group).
The antigen used in these studies is a 15-mer peptide, which has
been observed in our lab to possess anti-prostate cancer activity in
rats and produced a robust antibody response in vivo when
administered with an adjuvant [24]. The X-15 peptide was
conjugated to Keyhole Limpet Hemocyanin (KLH) (Pierce) and
injected subcutaneously. All the mice were vaccinated with 100 mg
of X-15, conjugated to KLH, on day 0 and received a booster of
50 mg of X-15 conjugated to KLH, on day 14. The difference
between groups was with the type of adjuvant used, which was
Alum, RS01, or RS09. Alum was added at a 1:1 (v:v) ratio to X-
15-KLH while both RS01 and RS09 were added at a
concentration of 25 mg. OVA peptide (8-mer peptide) served as
a negative non-adjuvant peptide control and also used at a
concentration of 25 mg. Blood was collected on days 0, 14, and 28.
The serum collected was used to determine the presence of X-15
specific antibodies via ELISA.
X-15 antibody ELISA
X-15 peptide specific antibody was determined by direct
ELISA. X-15 peptide was re-suspended in a solution of 0.25%
glutaraldehyde-PBS and 5 mg peptide/100 ml was added to each
well of a 96well micro titer plate and incubated overnight at 4uC.
The plates were washed with PBST (phosphate-buffered saline
with 0.05% Tween-20) three times and then wells blocked with
5% milk-PBS for 2 h at room temperature. The plates were
washed with PBST once. Then, 100 ml of mice sera was added at
the given dilution (1:200) and incubated at room temperature for
2 h. The plates were then washed with PBST four times and
100 ml of horse radish peroxidase (HRP) labeled anti-mouse IgG
(1:5000 in 2% milk) was added to each well for 1 H at room
temperature. The plates were washed five times with PBST and
developed by adding 100 ml of the HRP substrate, OPD–
hydrogen peroxide (Sigma). The reaction was stopped by adding
50 mlo f4NH 2SO4 and the absorbency was taken at 490 nm and
referenced at 405 nm.
Ethics Statement: The animal protocol used by our
laboratory in order to test the adjuvanticity of the LPS peptide
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Medical College) Institutional Animal Care and Use Committee
(IACUC), protocol approval number: 62-12-0610. The animals
were allowed to acclimate one week prior to initiating the
experiment and were at no time deprived of food or water. At the
time of experimentation, the animals were anesthetized via 3%
isoflurane inhalation and monitored daily to make sure they did
not have any adverse side effects. When blood was required for
analyses, the animals were once again anesthetized with 3%
isoflurane and blood was collected via retro-orbital sinus bleed by
the veterinary technicians from the Department of Comparative
Medicine of New York Medical College. At all times during the
experimental period, animals were not subjected to any stress.
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